atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results, Reports on R&D Progress and… Mar 30, 2022
atai Impact Donates to the Multidisciplinary Association for Psychedelic Studies (MAPS) to Support Pioneering Work in… Feb 16, 2022
atai Life Sciences Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health Treatments Jan 27, 2022
atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program Jan 12, 2022
atai Impact Establishes the atai Fellowship Fund in Psychedelic Neuroscience with Massachusetts General Hospital’s… Dec 16, 2021
Apeiron and Other Key Shareholders of atai Life Sciences Reinforce Support by Entering into Extended, Voluntary Share… Dec 15, 2021
